{"brief_title": "Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).", "brief_summary": "This is a randomized, double-blind, placebo-controlled, parallel-group forced up-titration study. Randomization will be stratified according to the patient's baseline serum sodium concentration (137-144 and <137 mmol/L). The dose of study drug will be increased to the next level on Day 15, and the total duration of the double-blind treatment period is 120 days.", "condition": "Chronic Heart Failure", "intervention_type": "Drug", "intervention_name": "Vasopressin V2 Receptor Antagonist", "criteria": "- Men or women with chronic heart failure (NYHA Class IIIB and IV). - Women must be post-menopausal or surgically sterilized; they cannot be pregnant or nursing. - Age 21 to 80 years. - Chronic heart failure of at least 3 months duration. For 2 months prior to screening, patients must have had symptoms at rest or on minimal exertion for more than 50% of the time. For 2 weeks prior to screening, patients must have had symptoms at rest or on minimal exertion for more than 90% of the time. - Patients must be receiving a diuretic and an ACE inhibitor (or an angiotensin II receptor antagonist) for the treatment of heart failure. - Patients may be receiving digoxin, a beta-blocker or spironolactone", "gender": "All", "minimum_age": "18 Years", "maximum_age": "80 Years", "healthy_volunteers": "No", "id": "NCT00032747.xml"}